Navigation Links
Major discovery on the mechanism of drug resistance in leukemia and other cancers
Date:5/28/2014

A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators. Kathy Borden is a Principal Investigator at IRIC and a professor at the university's Department of Pathology and Cell Biology. The development of drug resistance is one of the main problems in clinical oncology and the cause of relapse in many patients.

The new discovery, recently published in the prestigious scientific journal Nature, constitutes a major breakthrough in the fight against AML, one of the deadliest forms of leukemia, because it immediately suggests strategies to overcome drug resistance. Furthermore, the type of drug resistance the team identified is likely implicated in other cancers and a successful new treatment regimen based on these findings could have broad applications in treating cancer.

Previous work by Professor Borden's team had indicated that the use of ribavirin, a compound that was originally developed as an antiviral drug, could result in real benefits for certain cancer patients. With support from The Leukemia & Lymphoma Society of the USA, a first clinical trial using ribavirin to treat poor-prognosis AML patients was performed under the supervision of Dr. Sarit Assouline and Dr. Wilson Miller of the Segal Cancer Center at the Jewish General Hospital in Montral.

"This first clinical study yielded extremely promising results in most patients, including remissions, with no significant treatment-related toxicity. However, as is often the case when using a single drug, all patients eventually relapsed," recall Drs. Assouline and Miller. The multi-center study also included patients from the Hpital Maisonneuve-Rosemont (HMR) in Montreal and the McMaster University/Hamilton Health Sciences Center in Hamilton, Ontario.

In their recent article, the researchers describe why, in most of the patients, ribavirin as well as the standard chemotherapeutic drug cytarabine (Ara-C), eventually become ineffective at killing cancer cells. "By studying drug resistant cancer cells from AML patients and head and neck tumors, we found that a gene called "GLI1" is dramatically overactive in these cells," explains Hiba Zahreddine, doctoral student in the laboratory of Kathy Borden and first author of the Nature article. "With the help of our colleagues at Pharmascience Inc. we were then able to show that this results in a specific chemical change to the drugs, that prevents their toxicity toward the cancer cells," continues Professor Borden.

Fortunately, drugs that inhibit the activity of GLI1 are currently available and the scientists showed that these drugs could switch the cancer cells back into a ribavirin-sensitive state. It is hoped that when used in combination-therapy with ribavirin (or more standard chemotherapy), these drugs will prevent the development of drug resistance in patients. The team has now received approval from Health Canada to undertake a new clinical trial to test the novel drug combination in AML patients.

As part of its research partnership with Universit de Montral, Pharmascience Inc. will continue to manufacture and provide the ribavirin necessary for this clinical trial. "If this new approach is successful, it could have very broad applications since the mode of action of ribavirin suggests that it could be effective against up to 30% of all cancers including some types of breast, prostate, colon, stomach and head and neck cancers in addition to AML," explains Morris Goodman, co-founder and Chairman of the Board of Pharmascience Inc.


'/>"/>

Contact: William Raillant-Clark
rw.raillantclark@gmail.com
514-566-3813
University of Montreal
Source:Eurekalert

Related medicine news :

1. Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices
2. Therapy sought to reduce major risk from minor bleeding that can follow stroke
3. Major lung resection safer than ever, especially at the busiest hospitals
4. Genetic alterations in shared biological pathways as major risk factor for ASD
5. Gen X obesity a major problem for healthcare, workforce
6. Surgery after major stroke also improves survival odds in elderly patients
7. A majority prefers letting computers decide
8. Major third-hand smoke compound causes DNA damage -- and potentially cancer
9. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
10. Major League Baseball players win more games following Tommy John surgery
11. NYU researchers find majority of Latinas are unaware of their risk of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 2017 , ... Radabaugh & Associates, a locally owned firm ... in North Central West Virginia, is embarking on a cooperative charity drive with ... the region. , The Stepping Stones organization offers a series of personal development ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... advisory organization, is pleased to welcome Whipple & Company as its newest Partner ... clear purpose of balancing their clients’ risk while tailoring optimized benefit packages that ...
(Date:6/22/2017)... ... June 22, 2017 , ... The VA ... Maryland Recycling Network has awarded the Baltimore VA Medical Center, a division of ... Award for its efforts to promote waste reduction and promote recycling. Also, ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a premier ... private equity firm, has invested $3.35 million in the company. , “We ... Capital offers the smart money, speed to market and accountability we had been ...
(Date:6/20/2017)... FL (PRWEB) , ... June 20, 2017 , ... ... interactive health science curriculum , is pleased to announce a new online course ... accredited online course provides practical insights and evidence-based strategies for achieving optimal well-being ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
(Date:6/8/2017)... LOS ANGELES , June 8, 2017   Responding ... prescription drug oversight and the death of singer Chris ... Commission on Human Rights International offers a free online ...  to better educate consumers and families about psychotropic drug risks. ... Heath Ledger , who died from an accidental overdose, has ...
Breaking Medicine Technology: